All the news Showing 7 of 37 articles from: Hepatocellular carcinoma (HCC)Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Low uptake of HCV treatment in England will lead to substantial disease burden by 2035 Michael Carter / 24 June 2014 Only 3% of people with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of Hepatology. The current uptake of ... Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated Liz Highleyman / 19 November 2013 Hepatitis C treatment that leads to viral cure significantly reduces the likelihood of liver disease progression and liver-related mortality, but most people with hepatitis C remain untreated, according to a presentation at The Liver ... Drinking coffee halves the risk of liver cancer Michael Carter / 02 April 2013 Coffee consumption reduces the risk of liver cancer by approximately 50%, the results of a meta-analysis published in the online journal BMC Gastroenterology show. A total of 16 studies published before May 2012 ... Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis Michael Carter / 18 December 2012 Co-infection with HIV and viral hepatitis is associated with a more aggressive disease course for liver cancer, according to research conducted in London and presented to the recent EASL Monothematic Conference: HIV and ... Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising Liz Highleyman / 05 December 2012 The investigational cancer drug brivanib did not significantly increase survival for people with hepatocellular carcinoma over existing standard therapy, researchers reported at the recent Liver Meeting 2012, the 63rd Annual Meeting of ... Dramatic increase in incidence of liver cancer in HIV-positive people with viral hepatitis Michael Carter / 29 October 2012 Incidence of liver cancer among people with HIV has increased dramatically over the past decade, Spanish investigators report in the online edition of Clinical Infectious Diseases. All the cases involved individuals with ... Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity Liz Highleyman / 30 April 2012 The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumour activity, researchers reported at the 47th ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive